Description |
PLX4032, a targeted anticancer agent, selectively inhibits the cancer-causing BRAF(V600E) gene found in subsets of different cancers, including 70% of malignant melanomas and a significant number of colorectal and thyroid tumors. Plexxikon, the company developing PLX4032, will use a new test to detect the presence of this cancer-causing gene to identify patients most likely to respond to PLX4032, enabling a personalized form of treatment.
|
